Find a Doctor - Search by last name or narrow your search by gender or languages spoken
Find a Location - Search by specialty, city, or state
Chelation therapy is a chemical process in which a synthetic solution—EDTA (ethylenediaminetetraacetic acid)—is injected into the bloodstream to remove heavy metals and/or minerals from the body. Chelation means "to grab" or "to bind." When EDTA is injected into the veins, it "grabs" heavy metals and minerals such as lead, mercury, copper, iron, arsenic, aluminum, and calcium and removes them from the body. Except as a treatment for lead poisoning, chelation therapy is controversial and unproved.
Chelation therapy is performed on an outpatient basis.
helation is a very effective way to treat heavy-metal poisoning. The U.S. Food and Drug Administration (FDA) has approved prescription chelation therapy for the treatment of lead poisoning. Injected EDTA binds with the harmful metal and both are then eliminated from the body through the kidneys.
Some health professionals have also used chelation therapy to treat atherosclerosis and/or coronary artery disease, although there is not enough scientific evidence to prove that this treatment is effective. Some people believe that EDTA binds with calcium deposits (the part of plaque that obstructs the flow of blood to the heart) in the arteries, and then EDTA "cleans out" the calcium deposits from the arteries, reducing the risk of heart problems. Research results have been inconsistent.
Some health professionals also suspect that EDTA may act as an antioxidant by removing metals that combine with LDL cholesterol, which can damage arteries. The theory is that when you remove metals that flow freely through arteries (such as copper or calcium), you may slow down diseases such as atherosclerosis. Research has not proved this theory. Some experts believe that EDTA could remove calcium from healthy bones, muscles, and other tissues, as well as from diseased arteries.
Many people report less pain from chronic inflammatory diseases such as arthritis, lupus, and scleroderma after chelation therapy. The theory is that EDTA acts as an antioxidant, which protects the body from inflammation and protects blood vessels. Again, this idea has not been proved by scientific research.
Children, pregnant women, and people who have heart or kidney failure should not have chelation therapy at any dose.
Many years ago, chelation therapy was given in high doses and may have been linked to kidney damage, irregular heartbeats, and other serious consequences. Even when this treatment is given in low doses, some negative effects may occur, including high blood pressure, headache, rash, low blood sugar, and/or thrombophlebitis.
EDTA may remove vital minerals from the body along with the toxic metals. Vitamins and minerals are added to the EDTA solution to help keep them at an optimal level in the body to maintain health.
Always tell your doctor if you are using an alternative therapy or if you are thinking about combining an alternative therapy with your conventional medical treatment. It may not be safe to forgo your conventional medical treatment and rely only on an alternative therapy.
| By | Healthwise Staff |
|---|---|
| Primary Medical Reviewer | Adam Husney, MD, MD - Family Medicine |
| Specialist Medical Reviewer | Marc S. Micozzi, MD, PhD - Complementary and Alternative Medicine |
| Last Revised | June 29, 2011 |
Next Section:
Related InformationPrevious Section:
Topic OverviewNext Section:
CreditsPrevious Section:
Related InformationLast Revised: June 29, 2011
This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.
To learn more visit Healthwise.org
© 1995-2012 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.
RT @drdavidpearce: Early trigger for #alzheimers http://t.co/aQnGFDHYnT reported might be a target for #neurodegenerative & #rarediseases